Results 211 to 220 of about 69,426 (314)

A Study on Pharmacovigilance in the Hospitalized Pediatric Patients at Tertiary Care Hospital

Vipul Sheth, Dhaval Chauhan, Ganesh N. Sharma, S P Srinivas Nayak   +3 more
openalex   +1 more source

Pharmacovigilance for a Revolving World: Prospects of Patient-Generated Data on the Internet [PDF]

, 2014
G. Niklas Norén
openalex   +1 more source

Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age‐Related Studies in Thai Adults and Cross‐Population Comparisons

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Intrinsic factors such as age and ethnicity influence statin pharmacokinetics (PK) and may increase the risk of muscle‐related adverse events. This study investigated the effect of age on the PK of simvastatin (SV) and its active metabolite, simvastatin acid (SVA), in healthy Thai subjects using an LC–MS/MS assay while accounting for key ...
Thanate Srimatimanon, Udomsak Udomnilobol, Pajaree Chariyavilaskul, Sarawut Siwamogsatham, Kearkiat Praditpornsilpa, Yongkasem Vorasettakarnkij, Aisawan Petchlorlian, Natchaya Vanwong, Jittima Piriyapongsa, Pavita Tipsombatboon, Varalee Yodsurang, Thomayant Prueksaritanont   +11 more
wiley   +1 more source

LHS712_ADENotGood at #SMM4H 2024 Task 1: Deep-LLMADEminer: A deep learning and LLM pharmacovigilance pipeline for extraction and normalization of adverse drug event mentions on Twitter [PDF]

Yifan Zheng, Jun Gong, Shushun Ren, Dalton Simancek, V.G.Vinod Vydiswaran   +4 more
openalex   +1 more source

Effective stakeholder analysis and engagement: a vital strategy for enhanced pharmacovigilance systems in sub-Saharan Africa

, 2020
Babafunso A. Adenuga, Anastasia Aluvilu, Oluwaseun O. Olafusi, Dan Kibuule   +3 more
openalex   +2 more sources

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

, 2023
Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang   +3 more
openalex   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Evidence-based production framework for herbal medicine regulation in Indonesia. [PDF]

Front Pharmacol
Kashuri M, Ikrar T, Sutriyo, Mun'im A, Yanuar A.   +4 more
europepmc   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends. [PDF]

Hosp Pharm
Castellana E, Chiappetta MR.
europepmc   +1 more source